PF-06273340

• Description:

  PF-06273340 is a potent, selective, orally bioavailable and peripherally restricted pan Trk inhibitor[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Trk Receptor

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling; Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pf-06273340.html

• Purity:

  98.8

• Solubility:

  DMSO : 20 mg/mL (ultrasonic; warming)

• Smiles:

  O=C (NC1=CC (C (C2=CN (C (C) (C) CO) C3=NC (N) =NC=C32) =O) =CN=C1) CC4=NC=C (Cl) C=C4

• Molecular Formula:

  C23H22ClN7O3

• Molecular Weight:

  479.92

• Precautions:

  H302

• References & Citations:

  [1]Skerratt SE, et al. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  Trk

• CAS Number:

  1402438-74-7